Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.
Category
- Management of Immunotherapy-Related Toxicities
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy.
Category
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies
A better understanding of the pathogenesis of hematologic malignancies has led to the identification of new cytogenetic and molecular markers that distinguish between the various subtypes of hematologic malignancies. Informing hematologists and oncologists about the updated WHO5 classification and the new ICC will aid in the accurate diagnosis and development of a treatment plan to the specific subtype of hematologic malignancy.
Category
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma is a challenging disease state to treat and there are now numerous approved agents for this patient population. Clinicians would greatly benefit from additional education on the available agents and their place in therapy given the different modalities of treatment employed in relapsed/refractory disease.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification
Clinicians must understand the treatment evolution and guidelines for when to administer two-, three- or four- drug regimens as initial therapy in the context of the patient's therapeutic and disease history. Understanding how to individualize treatment will improve outcomes of patients with newly diagnosed MM.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Tackling Inequities in Multiple Myeloma: Practical Steps for Improving Access and Quality of Care
While there have been significant advancements in the management of multiple myeloma (MM) over the past decade, it is important to recognize that disparities in treatment and survival persist. Identifying patients who may be at risk for health inequity and implementing strategies to improve access and quality of care can help bridge current practice gaps and ensure equitable outcomes for all patients.
Category
- Disparities
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ASWB continuing education credit
- 1.00 Participation
Bone Disease Management and Infections in Multiple Myeloma
With improvement in treatment options and supportive care, patients with multiple myeloma (MM) are living longer. The majority of patients with MM are at risk for osteolytic bone lesions, osteoporosis, and infections among other complications. The outcomes of patients with MM can be improved by effective management of infections; recognizing and managing side effects of bone modifying therapy; and implementing plans of care to promote health, safety, mobility, and overall improved quality of life.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Updates to the Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. Clinicians would benefit from additional education on the available agents and understanding how to individualize treatment to improve outcomes of patients with MM.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation